Healthcare Triangle, Inc. (HCTI) 股票分析

公司概述

Healthcare Triangle, Inc. operates as a healthcare information technology company dedicated to developing specialized solutions within cloud services, data science, and professional managed services tailored for the electronic health record and life sciences sectors. The firm functions within the broader Healthcare sector, specifically targeting the Health Information Services industry, a domain where technological infrastructure is critical for data interoperability and operational efficiency in medical settings. The company maintains a market capitalization of $2.73 million and employs a workforce of 59 individuals to support its suite of software offerings. These valuation figures and revenue metrics of $12.94 million annually indicate that the company operates as a small-cap entity with a modest operational footprint, positioning it as a niche player rather than a large-scale market leader in the competitive health IT landscape.

财务健康

The company reported total revenue of $12.94 million over the trailing twelve months, yet posted a net income loss of $6,321,000 and an EBITDA of -$5,914,000, revealing a significant structural gap where operating expenses substantially exceed gross profits. This disparity highlights a cost structure where overhead and operational costs are aggressive relative to the top line, resulting in an operating margin of -74.3% and a profit margin of -48.8%. Additionally, the gross margin stands at 13.1%, which suggests that while the core product delivery retains some pricing power, the broader cost environment is challenging profitability. Free cash flow stands at -$11,508,500, indicating a substantial cash outflow that constrains financial flexibility and necessitates external capital or internal reserves to fund operations. On the balance sheet, the company holds $1.63 million in cash against $1.53 million in debt, resulting in a debt-to-equity ratio of 17.53. Despite the relatively low absolute debt amount, the high debt-to-equity ratio suggests a leveraged position relative to the company's equity base, while the current ratio of 2.03 indicates that current assets are more than double current liabilities, signaling adequate short-term liquidity to meet immediate obligations. Return on Equity is reported at -183.0% and Return on Assets at -39.3%, metrics that collectively reveal management is currently destroying shareholder value and failing to generate returns on the capital deployed in assets.

估值评估

The P/E Ratio (TTM) is listed as N/A due to the absence of positive earnings, while the Forward P/E is reported as -0.07, implying that the market is pricing in a trajectory where earnings may remain negative or are expected to recover from current losses. The price-to-book ratio is 0.13, indicating that the market values the company at significantly less than its net asset value, which often occurs when intangible assets or future growth potential are not fully reflected in the book value. The price-to-sales ratio of 0.21 and EV/EBITDA of -1.29 serve as alternative valuation metrics that suggest the stock is trading at a discount relative to its revenue generation, though the negative EV/EBITDA reflects the company's current inability to generate economic profit from operations. The stock has experienced extreme price volatility, with a 52-week high of $7,470.00 and a 52-week low of $2.24. Given the low price-to-sales context, the current trading price sits extremely close to the 52-week low, suggesting the market is pricing in significant downside risk or a complete re-rating of the business model. The Beta of 1.16 indicates that the stock is 16% more volatile than the broader market, meaning price swings will likely be amplified during periods of general market turbulence.

Growth & Income

Revenue growth year-over-year accelerated to 44.6%, demonstrating a rapid expansion in top-line sales, whereas earnings growth is N/A due to the company's persistent losses, implying that top-line expansion has not yet translated into bottom-line profitability. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash is retained within the company rather than distributed to shareholders. This reinvestment strategy aligns with the growth profile of a loss-making firm attempting to fund its R&D and operational scaling without external financing. Overall, the financial profile presents a high-growth revenue trajectory coupled with negative earnings and significant cash burn, creating a speculative income profile with no current yield.